Ftse Mib
34.151,41
-0,27%
DAX
18.498,38
0,32%
S&P 500
5.187,67
0,00%
NASDAQ
16.302,76
-0,18%
Bitcoin
60.877,29
-2,34%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ABVC BioPharma Inc (ABVC) ABVC BioPharma Inc (ABVC) Notizie

ABVC

ABVC BioPharma (ABVC)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ABVC
DataOraFonteTitoloSimboloCompagnia
18/04/202415:25GlobeNewswire Inc.AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareNASDAQ:ABVCABVC BioPharma Inc
17/04/202415:00GlobeNewswire Inc.ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MNASDAQ:ABVCABVC BioPharma Inc
10/04/202414:30GlobeNewswire Inc.ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MNASDAQ:ABVCABVC BioPharma Inc
26/03/202413:30GlobeNewswire Inc.ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MNASDAQ:ABVCABVC BioPharma Inc
21/03/202413:30GlobeNewswire Inc.AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsNASDAQ:ABVCABVC BioPharma Inc
19/03/202413:30GlobeNewswire Inc.ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia MagazineNASDAQ:ABVCABVC BioPharma Inc
14/03/202414:30GlobeNewswire Inc.ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateNASDAQ:ABVCABVC BioPharma Inc
29/02/202422:32Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ABVCABVC BioPharma Inc
27/02/202414:30GlobeNewswire Inc.ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion DollarsNASDAQ:ABVCABVC BioPharma Inc
16/02/202423:04Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:ABVCABVC BioPharma Inc
15/02/202414:30GlobeNewswire Inc.ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesNASDAQ:ABVCABVC BioPharma Inc
14/02/202401:59Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABVCABVC BioPharma Inc
12/02/202414:30GlobeNewswire Inc.ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)NASDAQ:ABVCABVC BioPharma Inc
08/02/202415:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABVCABVC BioPharma Inc
08/02/202415:17GlobeNewswire Inc.ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per ShareNASDAQ:ABVCABVC BioPharma Inc
12/01/202423:01Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:ABVCABVC BioPharma Inc
03/01/202413:24GlobeNewswire Inc.ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing FeesNASDAQ:ABVCABVC BioPharma Inc
07/12/202314:30GlobeNewswire Inc.ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical StudyNASDAQ:ABVCABVC BioPharma Inc
05/12/202314:30GlobeNewswire Inc.ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical TrialsNASDAQ:ABVCABVC BioPharma Inc
21/11/202314:30GlobeNewswire Inc.ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion MarketNASDAQ:ABVCABVC BioPharma Inc
17/11/202323:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:ABVCABVC BioPharma Inc
17/11/202323:00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ABVCABVC BioPharma Inc
16/11/202316:05GlobeNewswire Inc.ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200MNASDAQ:ABVCABVC BioPharma Inc
15/11/202315:00GlobeNewswire Inc.ABVC BioPharma Reports Third Quarter 2023 Financial and Operational ResultsNASDAQ:ABVCABVC BioPharma Inc
15/11/202314:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABVCABVC BioPharma Inc
26/10/202314:30GlobeNewswire Inc.ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 MillionNASDAQ:ABVCABVC BioPharma Inc
17/10/202314:30GlobeNewswire Inc.ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical StudyNASDAQ:ABVCABVC BioPharma Inc
09/10/202314:30GlobeNewswire Inc.ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)NASDAQ:ABVCABVC BioPharma Inc
23/08/202314:30GlobeNewswire Inc.ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical StudyNASDAQ:ABVCABVC BioPharma Inc
17/08/202315:19GlobeNewswire Inc.ABVC Executes Cooperation Agreement for Strategic InvestmentsNASDAQ:ABVCABVC BioPharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ABVC

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
RACE
Ferrari NV
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
LDO
Leonardo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
CPR
Davide Campari
BIT
BPE
Bper Banca
BIT
SPM
Saipem
BIT
FBK
Finecobank
BIT
TRN
Terna Trasmissione Elett...
BIT
IRE
Iren
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network